Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)

Detalhes bibliográficos
Autor(a) principal: Santos, Cliomar Alves dos
Data de Publicação: 2010
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFS
Texto Completo: https://ri.ufs.br/handle/riufs/3814
Resumo: Inflammation is an important component of many diseases whose core process is the phagocytic cell recruitment causing tissue damage. Plants with therapeutic use by the population are alternatives for the treatment of inflammatory diseases, among them Caesaplinia pyramidalis is popularly known as "catingueira", and the objective of this study is to investigated the anti-inflammatory, antinociceptive and antioxidant activities of the ethanol bark extract (EBE) of this semi-arid Northeast plant. The preliminary phytochemical screening of the EBE revealed the presence of the following classes of secondary metabolites: phenols, tannins, flavonoids, steroids, triterpenes, and saponins. Animals were pretreated with the EBE of C. pyramidalis (100, 200, and 400 mg/kg, p.o.) or vehicle (0.2% tween 80 in saline, 10 mL/kg, p.o.) 1 h before. Separate groups of animals were pretreated 1 h before with acetylsalicylic acid (ASA, 300 mg/kg, p.o., for writhing, formalin and paw edema tests), dexamethasone (2 mg/kg, s.c., for model of peritonitis and paw edema) or naloxona (5 mg/kg, i.p., for hot plate test) and 30 min before with morphine (3 or 10 mg/kg, i.p., for hot plate test and formaline test) or diazepam (1,5 mg/kg, i.p., for rota rod test) which were used as standard controls. To assess the antinociceptive activity we have used the acetic acid-induced writhing (0.6%, 0.1 mL/10g, i.p.), formalin (2%, 20 μL/paw) or hot plate models in Swiss mice (n = 6/group). The EBE, at the doses of 100, 200, and 400 mg/kg, significantly reduced (P < 0.001) the abdominal writhing in 20.9, 41.7, and 69.5%, respectively, as compared to control (31.17 ± 0.95 writhes). The extract at the doses of 100, 200 and 400 mg/kg decreases significantly the time that animals spent licking/bitting their paw during both phases of the formalin test (P < 0,05) and increased the latency of animals in the hot plate test in recorded times (P < 0,05), as well as morphine efect. Naloxone was capable of reversing the inhibition evoked by the EBE (400 mg/kg) on the hot plate model, as well as the morphine effect. In order to exclude a possible involvement in motor activity of the extract was performed to rota-rod test in which the results showed no statistical difference with the group that received vehicle. To evaluate the anti-inflammatory activity were used in vivo models of paw edema and peritonitis. In the paw edema model induced by 1% carrageenan (100 μL/paw, s.c.) in Wistar rats (n = 6/group), the EBE of C. pyramidalis at the dose of 400 mg/kg caused inhibition of 41.2% in the edema formation (P < 0.05). The recruitment of neutrophils to the swollen paw was indirectly measured by determining the MPO activity. Oral treatment of the animals with the EBE of C. pyramidalis (400 mg/kg) was able to reduce in 37.1% MPO 12 activity when compared with control (7,12 ± 0,94 UMPO/mg tissue, P < 0.05). In the peritonitis model in Swiss mice (n = 6/group), 4 h after injection of carrageenan (1%, 0.25 mL, i.p.), was observed that the EBE inhibited (P < 0.01) the leukocyte migration into the peritoneal cavity in 58,6% at the dose of 400 mg/kg, as compared to control (7,22 ± 0,99 x 106 leukocytes/mL). The differential count of leukocytes confirmed the decrease (P < 0.001) of the polymorphonuclear cells to the inflammatory site at the doses of 200 and 400 mg/kg. The antioxidant test used was the lipid peroxidation by thiobarbituric acid reactive species (TBARS) where an in vitro system of radical production (AAPH-2,2-azobis-2- metilpropionamidina) evaluated the EBE ability (1 - 1000 μg/mL) to modulate oxidative damage in a preparation of liposomes, using vitamin C (1.76 μg/mL) as control. The concentrations of the 100 and 1000 μg/mL of the EBE of C. pyramidalis reduced (P < 0.01) TBARS production, which strengthens the relationship between anti-inflammatory activity and antioxidant compounds. Concludes that the plant Caesalpinia pyramidalis has antiinflammatory, antinociceptive and antioxidant activities, supporting the use in popular medicine as anti-inflammatory agent. These biological activities may be related, at least in part, to the presence of tannins, flavonoids, and saponins.
id UFS-2_94319f90400d6a69eac2b14a02c7d8a3
oai_identifier_str oai:ufs.br:riufs/3814
network_acronym_str UFS-2
network_name_str Repositório Institucional da UFS
repository_id_str
spelling Santos, Cliomar Alves doshttp://lattes.cnpq.br/9879983198868216Thomazzi, Sara Mariahttp://lattes.cnpq.br/31082635495832012017-09-26T12:17:39Z2017-09-26T12:17:39Z2010-09-10SANTOS, Cliomar Alves dos. ESTUDO FARMACOLOGICO DO EXTRATO ETANOLICO DA ENTRECASCA DA CAESALPINIA PYRAMIDALIS TUL. (LEGUMINOSAE).. 2010. 85 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2010.https://ri.ufs.br/handle/riufs/3814Inflammation is an important component of many diseases whose core process is the phagocytic cell recruitment causing tissue damage. Plants with therapeutic use by the population are alternatives for the treatment of inflammatory diseases, among them Caesaplinia pyramidalis is popularly known as "catingueira", and the objective of this study is to investigated the anti-inflammatory, antinociceptive and antioxidant activities of the ethanol bark extract (EBE) of this semi-arid Northeast plant. The preliminary phytochemical screening of the EBE revealed the presence of the following classes of secondary metabolites: phenols, tannins, flavonoids, steroids, triterpenes, and saponins. Animals were pretreated with the EBE of C. pyramidalis (100, 200, and 400 mg/kg, p.o.) or vehicle (0.2% tween 80 in saline, 10 mL/kg, p.o.) 1 h before. Separate groups of animals were pretreated 1 h before with acetylsalicylic acid (ASA, 300 mg/kg, p.o., for writhing, formalin and paw edema tests), dexamethasone (2 mg/kg, s.c., for model of peritonitis and paw edema) or naloxona (5 mg/kg, i.p., for hot plate test) and 30 min before with morphine (3 or 10 mg/kg, i.p., for hot plate test and formaline test) or diazepam (1,5 mg/kg, i.p., for rota rod test) which were used as standard controls. To assess the antinociceptive activity we have used the acetic acid-induced writhing (0.6%, 0.1 mL/10g, i.p.), formalin (2%, 20 μL/paw) or hot plate models in Swiss mice (n = 6/group). The EBE, at the doses of 100, 200, and 400 mg/kg, significantly reduced (P < 0.001) the abdominal writhing in 20.9, 41.7, and 69.5%, respectively, as compared to control (31.17 ± 0.95 writhes). The extract at the doses of 100, 200 and 400 mg/kg decreases significantly the time that animals spent licking/bitting their paw during both phases of the formalin test (P < 0,05) and increased the latency of animals in the hot plate test in recorded times (P < 0,05), as well as morphine efect. Naloxone was capable of reversing the inhibition evoked by the EBE (400 mg/kg) on the hot plate model, as well as the morphine effect. In order to exclude a possible involvement in motor activity of the extract was performed to rota-rod test in which the results showed no statistical difference with the group that received vehicle. To evaluate the anti-inflammatory activity were used in vivo models of paw edema and peritonitis. In the paw edema model induced by 1% carrageenan (100 μL/paw, s.c.) in Wistar rats (n = 6/group), the EBE of C. pyramidalis at the dose of 400 mg/kg caused inhibition of 41.2% in the edema formation (P < 0.05). The recruitment of neutrophils to the swollen paw was indirectly measured by determining the MPO activity. Oral treatment of the animals with the EBE of C. pyramidalis (400 mg/kg) was able to reduce in 37.1% MPO 12 activity when compared with control (7,12 ± 0,94 UMPO/mg tissue, P < 0.05). In the peritonitis model in Swiss mice (n = 6/group), 4 h after injection of carrageenan (1%, 0.25 mL, i.p.), was observed that the EBE inhibited (P < 0.01) the leukocyte migration into the peritoneal cavity in 58,6% at the dose of 400 mg/kg, as compared to control (7,22 ± 0,99 x 106 leukocytes/mL). The differential count of leukocytes confirmed the decrease (P < 0.001) of the polymorphonuclear cells to the inflammatory site at the doses of 200 and 400 mg/kg. The antioxidant test used was the lipid peroxidation by thiobarbituric acid reactive species (TBARS) where an in vitro system of radical production (AAPH-2,2-azobis-2- metilpropionamidina) evaluated the EBE ability (1 - 1000 μg/mL) to modulate oxidative damage in a preparation of liposomes, using vitamin C (1.76 μg/mL) as control. The concentrations of the 100 and 1000 μg/mL of the EBE of C. pyramidalis reduced (P < 0.01) TBARS production, which strengthens the relationship between anti-inflammatory activity and antioxidant compounds. Concludes that the plant Caesalpinia pyramidalis has antiinflammatory, antinociceptive and antioxidant activities, supporting the use in popular medicine as anti-inflammatory agent. These biological activities may be related, at least in part, to the presence of tannins, flavonoids, and saponins.A inflamação é um importante componente de muitas doenças cujo processo central é o recrutamento de células fagocitárias provocando dano tecidual. As plantas com uso terapêutico pela população são alternativas para o tratamento de doenças inflamatórias, dentre elas está a Caesalpinia pyramidalis, conhecida popularmente como catingueira , a qual foi objeto deste estudo, que buscou investigar as propriedades anti-inflamatória, antinociceptiva e antioxidante do extrato etanólico da entrecasca (EEE) desta planta da região semiárida nordestina. A prospecção fitoquímica preliminar do EEE revelou as classes de metabólitos secundários presentes: fenóis, taninos, flavonóides, esteróides, triterpenos e saponinas. Os animais foram pré-tratados com o EEE da C. pyramidalis (100, 200 e 400 mg/kg, v.o.) ou com o veículo (tween 80 a 0,2% em salina, 10 mL/kg, v.o.) 1 h antes. Grupos separados de animais foram pré-tratados 1 h antes com ácido acetilsalicílico (AAS, 300 mg/kg, v.o., testes de contorções abdominais, formalina e edema de pata), dexametasona (2 mg/kg, s.c., modelos de peritonite e edema de pata) ou naloxona (5 mg/kg, i.p., teste da placa quente), e 30 min antes com morfina (3 ou 10 mg/kg, i.p., testes da placa quente e formalina) ou diazepam (1,5 mg/kg, i.p., teste de rota rod) os quais foram utilizados como controles padrão. Para avaliar a atividade antinociceptiva foram utilizados os modelos de contorções abdominais induzidas pelo ácido acético a 0,6% (0,1 mL, i.p.), formalina (2%, 20 μL/pata) ou placa quente em camundongos (Swiss, n=6/grupo). O EEE nas doses de 100, 200 e 400 mg/kg reduziu de forma significativa (P < 0,001) as contorções abdominais em 20,9, 41,7 e 69,5%, respectivamente, quando comparadas ao controle (31,17 ± 0,95 contorções abdominais). O EEE nas doses de 100, 200 e 400 mg/kg inibiu de forma significativa o tempo de lambida/mordida da pata dos camundongos em ambas as fases do teste de formalina (P < 0,05) e aumentou o tempo de latência dos animais na placa quente nos tempos registrados (P < 0,05). A naloxona foi capaz de reverter a inibição evocada pelo EEE (400 mg/kg) no modelo de placa quente, bem como o efeito da morfina. A fim de excluir uma possível intervenção do extrato na atividade motora foi realizado o teste da rota-rod no qual os resultados não mostraram diferença estatística com o grupo que recebeu o veículo. Para avaliar a atividade anti-inflamatória, foram utilizados os modelos in vivo de edema de pata e peritonite. No modelo de edema de pata induzido pela carragenina a 1% (100 μL/pata, s.c.) em ratos (Wistar, n=6/grupo), o EEE da C. pyramidalis na dose de 400 mg/kg causou inibição de 41,2% na formação do edema (P < 0,05). O recrutamento de neutrófilos para a pata 10 edemaciada foi medido indiretamente pela determinação da atividade da MPO. O tratamento oral dos animais com o EEE de C. pyramidalis (400 mg/kg) foi capaz de reduzir em 37,1% a atividade da MPO quando comparado ao controle (7,12 ± 0,94 UMPO/mg de tecido, P<0,05). No modelo de peritonite em camundongos (Swiss, n=6/grupo), 4 h após a injeção de carragenina (1%, 0,25 mL, i.p.), observou-se que o EEE inibiu (P < 0,01) a migração de leucócitos para a cavidade peritoneal em 58,6% na dose de 400 mg/kg, quando comparado ao controle (7,22 ± 0,99 x 106 leucócitos/mL). A contagem diferencial dos leucócitos demonstrou diminuição (P < 0,001) dos polimorfonucleares para o sítio inflamatório nas doses de 200 e 400 mg/kg. O teste antioxidante realizado foi a peroxidação lipídica pelas espécies reativas ao ácido tiobarbitúrico (TBARS) onde um sistema in vitro de produção de radicais (AAPH-2,2-azobis-2-metilpropionamidina) avaliou a capacidade do EEE (1 - 1000 μg/mL) em modular o dano oxidativo em uma preparação de lipossomnos, utilizando a vitamina C (1,76 μg/mL) como controle. As concentrações de 100 e 1000 μg/mL do EEE da C. pyramidalis mostraram atividade antioxidante reduzindo (P < 0,01) a produção de TBARS, o que reforça a relação anti-inflamatória com os compostos antioxidantes. Concluímos que a planta Caesalpinia pyramidalis possui atividades anti-inflamatória, antinociceptiva e antioxidante, embasando o uso popular como agente anti-inflamatório. Estas alterações biológicas devem estar relacionadas, ao menos em parte, à presença de taninos, flavonóides e saponinas.Conselho Nacional de Desenvolvimento Científico e Tecnológicoapplication/pdfporUniversidade Federal de SergipePós-Graduação em Ciências da SaúdeUFSBRAnti-inflamatórioAntinociceptivoAntioxidantesCaesalpinia pyramidalisLeguminosaeAnti-inflammatoryAntinociceptiveAntioxidantCaesalpinia pyramidalisLeguminosCNPQ::CIENCIAS DA SAUDE::MEDICINAEstudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSTEXTCLIOMAR_ALVES_SANTOS.pdf.txtCLIOMAR_ALVES_SANTOS.pdf.txtExtracted texttext/plain157864https://ri.ufs.br/jspui/bitstream/riufs/3814/2/CLIOMAR_ALVES_SANTOS.pdf.txtef3a87643a485e332a343f742795e860MD52THUMBNAILCLIOMAR_ALVES_SANTOS.pdf.jpgCLIOMAR_ALVES_SANTOS.pdf.jpgGenerated Thumbnailimage/jpeg1286https://ri.ufs.br/jspui/bitstream/riufs/3814/3/CLIOMAR_ALVES_SANTOS.pdf.jpg4fd137f37c1709ee21f2ceaab387299eMD53ORIGINALCLIOMAR_ALVES_SANTOS.pdfapplication/pdf1020677https://ri.ufs.br/jspui/bitstream/riufs/3814/1/CLIOMAR_ALVES_SANTOS.pdfe1c39e4e351cd638cc4db02cb8a11d52MD51riufs/38142017-11-28 16:44:15.371oai:ufs.br:riufs/3814Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2017-11-28T19:44:15Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false
dc.title.por.fl_str_mv Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
title Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
spellingShingle Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
Santos, Cliomar Alves dos
Anti-inflamatório
Antinociceptivo
Antioxidantes
Caesalpinia pyramidalis
Leguminosae
Anti-inflammatory
Antinociceptive
Antioxidant
Caesalpinia pyramidalis
Leguminos
CNPQ::CIENCIAS DA SAUDE::MEDICINA
title_short Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
title_full Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
title_fullStr Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
title_full_unstemmed Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
title_sort Estudo farmacologico do extrato etanolico da entrecasca da Caesalpinia pyramidalis Tul. (Leguminosae)
author Santos, Cliomar Alves dos
author_facet Santos, Cliomar Alves dos
author_role author
dc.contributor.author.fl_str_mv Santos, Cliomar Alves dos
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/9879983198868216
dc.contributor.advisor1.fl_str_mv Thomazzi, Sara Maria
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/3108263549583201
contributor_str_mv Thomazzi, Sara Maria
dc.subject.por.fl_str_mv Anti-inflamatório
Antinociceptivo
Antioxidantes
Caesalpinia pyramidalis
Leguminosae
topic Anti-inflamatório
Antinociceptivo
Antioxidantes
Caesalpinia pyramidalis
Leguminosae
Anti-inflammatory
Antinociceptive
Antioxidant
Caesalpinia pyramidalis
Leguminos
CNPQ::CIENCIAS DA SAUDE::MEDICINA
dc.subject.eng.fl_str_mv Anti-inflammatory
Antinociceptive
Antioxidant
Caesalpinia pyramidalis
Leguminos
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::MEDICINA
description Inflammation is an important component of many diseases whose core process is the phagocytic cell recruitment causing tissue damage. Plants with therapeutic use by the population are alternatives for the treatment of inflammatory diseases, among them Caesaplinia pyramidalis is popularly known as "catingueira", and the objective of this study is to investigated the anti-inflammatory, antinociceptive and antioxidant activities of the ethanol bark extract (EBE) of this semi-arid Northeast plant. The preliminary phytochemical screening of the EBE revealed the presence of the following classes of secondary metabolites: phenols, tannins, flavonoids, steroids, triterpenes, and saponins. Animals were pretreated with the EBE of C. pyramidalis (100, 200, and 400 mg/kg, p.o.) or vehicle (0.2% tween 80 in saline, 10 mL/kg, p.o.) 1 h before. Separate groups of animals were pretreated 1 h before with acetylsalicylic acid (ASA, 300 mg/kg, p.o., for writhing, formalin and paw edema tests), dexamethasone (2 mg/kg, s.c., for model of peritonitis and paw edema) or naloxona (5 mg/kg, i.p., for hot plate test) and 30 min before with morphine (3 or 10 mg/kg, i.p., for hot plate test and formaline test) or diazepam (1,5 mg/kg, i.p., for rota rod test) which were used as standard controls. To assess the antinociceptive activity we have used the acetic acid-induced writhing (0.6%, 0.1 mL/10g, i.p.), formalin (2%, 20 μL/paw) or hot plate models in Swiss mice (n = 6/group). The EBE, at the doses of 100, 200, and 400 mg/kg, significantly reduced (P < 0.001) the abdominal writhing in 20.9, 41.7, and 69.5%, respectively, as compared to control (31.17 ± 0.95 writhes). The extract at the doses of 100, 200 and 400 mg/kg decreases significantly the time that animals spent licking/bitting their paw during both phases of the formalin test (P < 0,05) and increased the latency of animals in the hot plate test in recorded times (P < 0,05), as well as morphine efect. Naloxone was capable of reversing the inhibition evoked by the EBE (400 mg/kg) on the hot plate model, as well as the morphine effect. In order to exclude a possible involvement in motor activity of the extract was performed to rota-rod test in which the results showed no statistical difference with the group that received vehicle. To evaluate the anti-inflammatory activity were used in vivo models of paw edema and peritonitis. In the paw edema model induced by 1% carrageenan (100 μL/paw, s.c.) in Wistar rats (n = 6/group), the EBE of C. pyramidalis at the dose of 400 mg/kg caused inhibition of 41.2% in the edema formation (P < 0.05). The recruitment of neutrophils to the swollen paw was indirectly measured by determining the MPO activity. Oral treatment of the animals with the EBE of C. pyramidalis (400 mg/kg) was able to reduce in 37.1% MPO 12 activity when compared with control (7,12 ± 0,94 UMPO/mg tissue, P < 0.05). In the peritonitis model in Swiss mice (n = 6/group), 4 h after injection of carrageenan (1%, 0.25 mL, i.p.), was observed that the EBE inhibited (P < 0.01) the leukocyte migration into the peritoneal cavity in 58,6% at the dose of 400 mg/kg, as compared to control (7,22 ± 0,99 x 106 leukocytes/mL). The differential count of leukocytes confirmed the decrease (P < 0.001) of the polymorphonuclear cells to the inflammatory site at the doses of 200 and 400 mg/kg. The antioxidant test used was the lipid peroxidation by thiobarbituric acid reactive species (TBARS) where an in vitro system of radical production (AAPH-2,2-azobis-2- metilpropionamidina) evaluated the EBE ability (1 - 1000 μg/mL) to modulate oxidative damage in a preparation of liposomes, using vitamin C (1.76 μg/mL) as control. The concentrations of the 100 and 1000 μg/mL of the EBE of C. pyramidalis reduced (P < 0.01) TBARS production, which strengthens the relationship between anti-inflammatory activity and antioxidant compounds. Concludes that the plant Caesalpinia pyramidalis has antiinflammatory, antinociceptive and antioxidant activities, supporting the use in popular medicine as anti-inflammatory agent. These biological activities may be related, at least in part, to the presence of tannins, flavonoids, and saponins.
publishDate 2010
dc.date.issued.fl_str_mv 2010-09-10
dc.date.accessioned.fl_str_mv 2017-09-26T12:17:39Z
dc.date.available.fl_str_mv 2017-09-26T12:17:39Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv SANTOS, Cliomar Alves dos. ESTUDO FARMACOLOGICO DO EXTRATO ETANOLICO DA ENTRECASCA DA CAESALPINIA PYRAMIDALIS TUL. (LEGUMINOSAE).. 2010. 85 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2010.
dc.identifier.uri.fl_str_mv https://ri.ufs.br/handle/riufs/3814
identifier_str_mv SANTOS, Cliomar Alves dos. ESTUDO FARMACOLOGICO DO EXTRATO ETANOLICO DA ENTRECASCA DA CAESALPINIA PYRAMIDALIS TUL. (LEGUMINOSAE).. 2010. 85 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Sergipe, Aracaju, 2010.
url https://ri.ufs.br/handle/riufs/3814
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Sergipe
dc.publisher.program.fl_str_mv Pós-Graduação em Ciências da Saúde
dc.publisher.initials.fl_str_mv UFS
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade Federal de Sergipe
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFS
instname:Universidade Federal de Sergipe (UFS)
instacron:UFS
instname_str Universidade Federal de Sergipe (UFS)
instacron_str UFS
institution UFS
reponame_str Repositório Institucional da UFS
collection Repositório Institucional da UFS
bitstream.url.fl_str_mv https://ri.ufs.br/jspui/bitstream/riufs/3814/2/CLIOMAR_ALVES_SANTOS.pdf.txt
https://ri.ufs.br/jspui/bitstream/riufs/3814/3/CLIOMAR_ALVES_SANTOS.pdf.jpg
https://ri.ufs.br/jspui/bitstream/riufs/3814/1/CLIOMAR_ALVES_SANTOS.pdf
bitstream.checksum.fl_str_mv ef3a87643a485e332a343f742795e860
4fd137f37c1709ee21f2ceaab387299e
e1c39e4e351cd638cc4db02cb8a11d52
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)
repository.mail.fl_str_mv repositorio@academico.ufs.br
_version_ 1802110703932276736